European DataWarehouse Opens Bangalore Office
European DataWarehouse (EDW), Europe’s first securitisation repository, today announced the opening of a new office in Bangalore, India. This strategic expansion underscores EDW’s continued commitment to technological innovation and excellence in client service across global markets.
The Bangalore office will serve as a center for IT operations, software development, and support for EDW’s flagship platforms, EDITOR and EDVANCE. It will also enable round-the-clock service for clients operating in non-European time zones and bring previously outsourced IT services in-house—enhancing security, responsiveness, and development agility.
The new office will be led by Gopala Sankaran, Chief Technology Officer at European DataWarehouse, who joined the company in 2014 and brings extensive expertise in global tech strategy and development.
Dr. Christian Thun, CEO of European DataWarehouse, commented:
“Establishing a presence in India is an important and exciting step for EDW. Bangalore is home to some of the world’s best technology talent, and this expansion enables us to accelerate innovation while enhancing service for our clients across continents.”
Gopala Sankaran, CTO, added:
“We’re proud to deepen our global footprint with a vibrant new base in Bangalore. This office not only allows us to scale up development of our regulatory product portfolio but also to serve our clients more efficiently, no matter where they are in the world. It’s a strong step forward in our mission to deliver reliable, forward-thinking solutions in the securitisation space and beyond.”
The Bangalore team will play a key role in supporting European DataWarehouse’s growing global user base and driving the evolution of its technology platform in a dynamic financial landscape.
The establishment of the Bangalore office marks a significant milestone in European DataWarehouse’s international expansion. It becomes the company’s third operational location, complementing its headquarters in Frankfurt, Germany, and the London office, which opened in 2018 to support operations of EDW’s UK subsidiary, European DataWarehouse Ltd.
About European DataWarehouse GmbH
European DataWarehouse (EDW) is a designated Securitisation Repository, authorised by both the European Securities and Markets Authority (ESMA) and the UK’s Financial Conduct Authority (FCA). Established in 2012, EDW was the first repository of its kind in Europe, created to improve transparency and support due diligence in the asset-backed securities (ABS) market.
EDW collects, validates, and provides access to standardised loan-level data and related documentation for ABS transactions and private whole loan portfolios. By serving as a central data hub, EDW enables investors, issuers, and regulators to efficiently analyse and compare portfolios, fostering greater trust and efficiency in the securitisation ecosystem.
To learn more or stay up to date with our latest insights and developments, visit www.eurodw.eu / www.eurodw.co.uk or follow us on LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250519115304/en/
Contacts
Media Contact:
European DataWarehouse GmbH
Diane Vogelpohl
Marketing & Communications Manager
Tel. 49 (0) 69 50986 9326
Email: diane.vogelpohl@eurodw.eu
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CCM Biosciences Announces Presentation of Data on its First-In-Class AML Drug Program at ASCO 202520.5.2025 23:30:00 EEST | Press release
CCM Biosciences, a diversified pharmaceutical discovery and development company, today announced the upcoming presentation of its next-generation FLT3 inhibitor drug program for acute myeloid leukemia (AML) at the 2025 Annual Conference of the American Society of Clinical Oncology (ASCO), taking place May 30 to June 3 in Chicago. Acute Myeloid Leukemia (AML) is the most severe form of leukemia with few treatment options, and a malignancy frequently driven by mutations in the FMS-like tyrosine kinase 3 (FLT3) gene. The FLT3 internal tandem duplication (ITD) and tyrosine kinase domain (TKD) mutations, particularly D835 and F691, appear in approximately 30% of AML patients, often leading to poor prognosis and resistance to existing therapies. Gilteritinib (Xospata®; Astellas Pharma, peak annual sales projection: $1.5 billion) and Quizartinib (Vanflyta®; Daiichi Sankyo) are two FDA-approved FLT3 inhibitors, with the former approved only for relapsed/refractory AML and the latter approved o
IonQ Partners with Sweden’s Einride to Develop Quantum Supply Chain and Quantum-Enhanced Logistics for Autonomous Driving Solutions20.5.2025 23:05:00 EEST | Press release
IonQ (NYSE: IONQ), a leading commercial quantum computing and networking company, today announced an investment partnership with Einride, a leading global freight mobility company that provides digital, electric, and autonomous technology to explore how quantum computing can drive the next generation of fleet optimization and logistics. Together, IonQ and Einride will develop quantum applications that address large-scale routing and scheduling problems that have traditionally challenged classical computing. By combining IonQ’s advanced quantum systems with Einride’s expertise in autonomous fleet logistics, the two companies will work to unlock new levels of efficiency, reliability, and sustainability for the global freight industry. “Einride shares our belief that quantum computing will fundamentally reshape and improve how large industries such as transportation and logistics operate,” said Niccolo de Masi, CEO of IonQ. “This partnership is aimed at creating a powerful platform with u
CCM Biosciences Announces Presentation of Data on its First-In-Class NSCLC Drug Program at ASCO 202520.5.2025 22:26:00 EEST | Press release
CCM Biosciences, a diversified pharmaceutical discovery and development company, today announced the upcoming presentation of its 4th-generation EGFR inhibitor drug program for non-small cell lung cancer (NSCLC) at the 2025 Annual Conference of the American Society of Clinical Oncology (ASCO), taking place May 30 to June 3 in Chicago. NSCLC, which accounts for 80% of lung cancer, is the most common cause of cancer death worldwide. Epidermal growth factor receptor (EGFR)-activating mutations (Del19 or L858R) are major oncogenic drivers of NSCLC. EGFR-positive NSCLC accounts for approximately 30% of all diagnosed cases of NSCLC (a similar market size to PD-L1-positive NSCLC, which is addressed by the world’s top-selling drug, Keytruda®). The current standard of care for EGFR-positive NSCLC is comprised of 3rd-generation inhibitors, most notably Osimertinib (Tagrisso®), whose annual sales exceed $6 billion. Most patients treated by tyrosine kinase inhibitors (TKIs) will eventually develop
NielsenIQ's Chief Technology Officer Mohit Kapoor Named Executive of the Year at Global Tech & AI Awards for Leading NIQ’s AI-Driven Tech Transformation20.5.2025 22:24:00 EEST | Press release
NielsenIQ (NIQ) is proud to announce that Mohit Kapoor, Chief Technology Officer, was named Executive of the Year at the inaugural Global Tech & AI Awards. This honor recognizes Mohit's exceptional leadership and visionary contributions to the tech industry, particularly in the realm of AI-powered consumer intelligence. "I am deeply honored to receive the Executive of the Year award at the Global Tech & AI Awards. This recognition is a testament to the incredible work and dedication of the entire NielsenIQ team,” said Mohit Kapoor, Chief Technology Officer, NIQ. “Together, we have redefined consumer and retail intelligence, leveraging AI to deliver unparalleled insights and drive meaningful change in the industry." Under Mohit's leadership, NIQ has adopted an AI-powered approach to its ambitious digital transformation which included a $400 million technology investment and the migration of its global client base onto Discover– a unified, cloud-based platform that seamlessly integrates
Strategic Partnership Between the Government of Morocco and TAQA Morocco, Nareva, ONEE and the Mohammed VI Investment Fund to Develop Key Power and Water Infrastructures in the Kingdom of Morocco20.5.2025 22:08:00 EEST | Press release
As part of the implementation of the commitments made in the joint declaration between His Majesty King Mohammed VI, may God Assist Him, and His Highness Sheikh Mohamed bin Zayed Al Nahyan, TAQA Morocco, in partnership with Nareva and the Mohammed VI Fund for Investment, has signed three memorandums of understanding and related development agreements with the Government of Morocco and ONEE. These agreements cover the development of structuring projects in the power, water and renewable energy sectors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250520313620/en/ Strategic Partnership Between the Government of Morocco and TAQA Morocco, Nareva, ONEE and the Mohammed VI Investment Fund to Develop Key Power and Water Infrastructures in the Kingdom of Morocco (Photo: AETOSWire) The program aims to strengthen the Kingdom's water and energy sovereignty through the development of flexible natural gas-based power generation capacit
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom